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Background: Sciatica is a common condition reported to affect over 3% of the UK population at any time and is
often caused by a prolapsed intervertebral disc (PID). Although the duration and severity of symptoms can vary,
pain persisting beyond 6 weeks is unlikely to recover spontaneously and may require investigation and treatment.
Currently, there is no specific care pathway for sciatica in the National Health Service (NHS), and no direct
comparison exists between surgical microdiscectomy and transforaminal epidural steroid injection (TFESI). The
NERVES (NErve Root block VErsus Surgery) trial aims to address this by comparing clinical and cost-effectiveness of
surgical microdiscectomy and TFESI to treat sciatica secondary to a PID.
Methods/design: A total of 163 patients were recruited from NHS out-patient clinics across the UK and randomised to
either microdiscectomy or TFESI. Adult patients (aged 16–65 years) with sciatic pain endured for between 6 weeks and
12 months are eligible if their symptoms have not been improved by at least one form of conservative (non-operative)
treatment and they are willing to provide consent. Patients will be excluded if they present with neurological deficit or
have had previous surgery at the same level. The primary outcome is patient-reported disability measured using the
Oswestry Disability Questionnaire (ODQ) score at 18 weeks post randomisation and secondary outcomes include
disability and pain scales using numerical pain ratings, modified Roland-Morris and Core Outcome Measures Index at
12-weekly intervals, and patient satisfaction at 54 weeks. Cost-effectiveness and quality of life (QOL) will be assessed
using the EQ-5D-5 L and self-report cost data at 12-weekly intervals and Hospital Episode Statistics (HES) data. Adverse
event data will be collected. Analysis will follow the principle of intention-to-treat.
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Discussion: NERVES is the first trial to evaluate the comparative clinical and cost-effectiveness of microdiscectomy to
local anaesthetic and steroid administered via TFESI. The results of this research may facilitate the development of an
evidence-based treatment strategy for patients with sciatica.
Trial registration: ISRCTN, ID: ISRCTN04820368. Registered on 5 June 2014.
EudraCT EudraCT2014–002751-25. Registered on 8 October 2014.
Keywords: Sciatica, Microdiscectomy, Transforaminal epidural steroid injection, Prolapsed intervertebral disc,
Randomised controlled trialBackground
Sciatica is broadly defined as leg pain in the distribution
of a lumbosacral nerve root [1]. It is a common condi-
tion affecting over 3% of the population at any one time
and over 90% of sciatica is due to a prolapsed interverte-
bral disc (PID) [2]. Patients affected are typically young,
working adults and it can be helpful to consider three
categories of sciatica: (1) acute sciatica – lasts less than
6 weeks and may be self-limiting with little or no impact
on the patient’s ability to perform usual activities; (2)
chronic sciatica – persists beyond 6 weeks and has a tre-
mendous impact upon the patient’s working ability and
(3) resistant sciatica – persists beyond 12 months [3].
Although the duration of pain may vary considerably,
and the natural history of sciatica is favourable within 1
year, many patients have pain that persists beyond
6 weeks which could have considerable impact upon the
employment market and patients’ lives [4]. It is generally
accepted that pain persisting beyond 6 weeks is unlikely
to get better imminently and requires further investiga-
tion and treatment [1–4]. There is no current accepted
treatment paradigm for sciatica within the UK [1]. Treat-
ment options are largely uproven but include analgesic
drugs of various categories including antiepileptics and
antidepressants, injections of drug combinations into the
spine and surgical techniques to remove the prolapsed
disc [1] Recent evidence has suggested that the com-
monly used neuromodulator drug pregabalin may not
have a strong benefit in the treatment of sciatica in the
community [5]. Epidural steroid injections (ESI) are
another treatment modality for sciatica and involve the
administration of a mixture of local anaesthetic and ster-
oid into the spine via one of three main routes; through
the base of the spine (caudal epidural), through the back
of the spine (inter-laminar) or through the nerve tunnel
directly adjacent to the prolapsed disc (transforaminal
epidural steroid injection (TFESI) [6]. Randomised con-
trolled trials (RCTs) have looked at ESI for acute sciatica
but these have not included comparisons between TFESI
and inter-laminar ESI [7–10]. However, prospective and
case control studies have compared these and demon-
strated a superior efficacy of TFESI [6–9]. One recent
study of TFESI ([9]; n = 238) reported that 65% ofinjections were effective at follow-up greater than
6 months (based on patient-reported measures) suggest-
ing that the administration of drug closer to the disc
prolapse may improve efficacy when compared to other
methods of administration. Moreover, efficacy is im-
proved if symptom duration is less than 6 months prior
to injection [9]. Only one trial [10]; n = 100) has directly
compared inter-laminar ESI to surgery for sciatica sec-
ondary to PID and suggested that ESI could prevent 50%
of surgical interventions. Although this specific use of
steroid is outside the marketing authorisation (off-label)
it is commonly used and a widely accepted treatment for
sciatica. Of the surgical techniques, microdiscectomy to
remove the prolapsed disc is considered the ‘gold standard’
with reported success rates of 90% [11]. As sciatica has a
good natural history there is potential that the treatment
administered in the form of injection may render surgery
as excessive, but results from other studies have shown that
ESI only have a small short-term effect on leg pain and dis-
ability compared with placebo, and no effect in the long
term [12]. These poor medium- to long-term results have
given ESI poor perceived efficacy and hence they are widely
ignored in the treatment of acute sciatica [13]. Perhaps
because of this at the time of trial conception no care
pathway in the National Health Service (NHS) suggests
any particular treatment over another [1]. No direct
comparison exists between surgical microdiscectomy to
treat sciatica secondary to lumber disc prolapse and nerve
root blocks such as TFESI. In the UK in 2010/2011 over
25,000 therapeutic ESIs were administered and over 9000
surgical procedures were performed to remove herniated
lumbar disc prolapses for sciatica (HES data). The costs to
the NHS in the United Kingdom (UK) are £600 per ESI
and approximately £4000 for surgical microdiscectomy
(which requires an average of two nights in hospital per
patient) [14].
The NERVES (NErve Root block VErsus Surgery) trial
is funded to compare surgical microdiscectomy to local
steroid and anaesthetic administered accurately to the
source of leg pain in terms against various clinical and
quality of life (QOL) outcomes to determine if there
should be a recommended treatment pathway for
patients with sciatica secondary to a PID. Surgical
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local NHS policy. Given the cost differential between the
interventions being evaluated, and the potential for dif-
ferences in clinical benefit and health outcomes, an eco-
nomic evaluation will be conducted alongside the trial to
determine which treatment option is the best use of
health-care resources.The primary objective is to com-
pare the clinical effectiveness of TFESI and surgical
microdiscectomy for sciatica secondary to PID. Secondary
objectives are to compare the cost-effectiveness of TFESI
and microdiscectomy for the treatment of sciatica
secondary to PID and to compare QOL outcomes for
both treatments.
Methods/design
Study design and setting
NERVES is a two-arm, multi-centre, phase III, randomised
trial comparing TFESI to surgical microdiscectomy for sci-
atic pain secondary to a PID. A Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) flow-
chart summarising the study protocol is presented in Fig. 1
(see Additional file 1 for the SPIRIT Checklist). Recruit-
ment will occur in NHS out-patient neurosurgical, pain
and orthopaedic clinics. Sites have been selected prag-
matically, prior to opening a site suitability assessment
including screening for the required patient volume was
completed. Eligible patients who provided consent were
randomised to TFESI and microdiscectomy in a ratio of
1:1 using an online computerised service. The schedule
will be generated by an independent statistician, stratified
by site, using permuted blocks of random sizes. Due to the
nature of the procedures involved it was not possible to
blind the participants.TFESI
6
Baseline
1-8
Microdiscectomy
6
Randomisation (1:1)
18 week follow up
1-11
30 week follow up
1-6 & 10-11
42 week follow up
1-6 & 10-11
54 week follow up
1-11
Fig. 1 Schematic of trial designPatients will be followed up for 54 weeks from the
date of randomisation with follow-up visits scheduled at
18 weeks, 30 weeks, 42 weeks and 54 weeks (12-week
intervals assuming treatment at 6 weeks).
Patients who have additional treatment after receiving
their randomised treatment or, who do not receive their
randomised treatment and instead crossover and receive
the other treatment will continue with the scheduled
follow-up visits, they will not be withdrawn from the trial.
All participants will complete trial assessments as
shown in Fig. 2.
Internal pilot
The original trial design includes an internal pilot phase
allowing analysis of 6 months of recruitment data from
two sites before progressing to full trial. The criteria for
progression to full trial are:
 At least 30 patients recruited
 Consent rate of 40% or more
 Fewer than 10% of patients unhappy with allocation
and receive the alternative treatment
 Fewer than 50% of patients in the injection group
proceed to surgery
Study population
The trial is open to adult patients with sciatica secondary
to a PID who meet the eligibility criteria listed in Table 1.
Contraindications for both arms of treatment are to be
assessed on a case-by-case basis by the healthcare team as
per routine NHS practice and according to local policy.
Written informed consent will be obtained for all patients
before any study-specific assessments are conducted. OnlyAssessments/Patient Reported Outcomes:
1. Oswestry Disability Questionnaire (ODQ) 
2. Roland Morris
3. Core Outcome Measures Index (COMI) 
4. Numerical pain scores for leg and back
5. EQ-5D-5L
6. Resource Use Questionnaire (RUQ)
7. Physical examination
8. Pregnancy
9. Concomitant medications
10. Return to work
11. Likert scale (treatment satisfaction)
12. Adverse events
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Signed Consent Form X
Assessment of Eligibility Criteria X
Review of Medical History X
Review of Concomitant Medications X X X X
Oswestry Disability Questionnaire X1 X X3 X3 X
Resource Use Questionnaire X1 X X X3 X3 X
EQ-5D-5L X1 X X3 X3 X
Numerical rating score for leg and back pain X1 X X3 X3 X
Modified Roland-Morris outcome score for sciatica X1 X X3 X3 X
Core Outcome Measures Index (COMI) X1 X X3 X3 X
Study Intervention X
Physical Examination  X X X
Pregnancy X X X
Treatment satisfaction (Likert scale) X X
Return to work X X
Assessment of Related Adverse Events X X X X
Assessment of additional interventions given to the 
participant during the trial period
X X X5
Telephone follow up of non-responders (X)4 (X)4
(X) – As indicated/appropriate.
1 Completed prior to randomisation 
2 Treatment is expected to occur within 6 weeks of randomisation
3 Patient is not required to attend clinic at 30 and 42 weeks; Questionnaire posted to the participant by the trial site and posted 
back to the trial coordinating centre
4 Telephone follow up will typically follow one week after initial issue of questionnaire
5 Additional visits for further treatment (e.g. TFESI or surgery) may occur as part of routine practice
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure. Trial assessments
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6 weeks of duration and who have tried at least one
non-invasive treatment form were selected.
Trial interventions
After baseline assessments have been completed and eli-
gibility confirmed, patients were randomised to receive
either an injection or surgery (1:1). Treatment was given
within 6 weeks of randomisation where possible and
should occur within 12 weeks of randomisation to en-
sure valid collection of primary outcome data at the
18-week follow-up. During the course of follow-up par-
ticipants may require further intervention for acute
sciatica as per routine NHS practice.
Transforaminal epidural steroid injection
TFESI is a standard nerve root blockade that will be per-
formed as per local policy using the lateral foraminal
portal of entry and guided fluoroscopically (i.e. compu-
terised tomography (CT) or x-ray) to identify the correct
level. As this is a pragmatic trial the agents used areexpected to be obtained and prescribed via normal NHS
routes. To minimise variability across the participating
sites it is expected that the following injection regimen
will be followed where possible: steroid: 20–60 mg
triamcinolone, e.g. Kenalog; local anaesthetic: 0.25%
levobupivacaine (2 ml), e.g. Chirocaine. Information on
exact dosage and agents used, the level of injection and
whether the block was preganglionic (at the level of the
index disc) or postganglionic (the level below the disc)
will be collected. All patients randomised to TFESI will
receive at least one therapeutic injection, but may also
be offered additional injections if there was partial or
short-term benefit from the first injection. TFESI is an
off-label use of steroid, but is commonly accepted prac-
tice within the NHS and in the wider medical field.
Surgical microdiscectomy
Standard microdiscectomy will be performed as per local
treatment protocols. Sites will identify the correct side
(left or right) and level prior to treatment with level
localisation advised as per local treatment protocols.
Table 1 Inclusion and exclusion criteria
Inclusion criteria:
• Diagnosed lower-extremity radiculopathy (sciatica)
• Sciatica secondary to prolapsed intervertebral disc (PID) (proven on
magnetic resonance imaging (MRI))
• Duration of symptoms between 6 weeks and 12 months
• Leg pain non-responsive to conservative, non-invasive management
• Age 16–65 years
• Patient has attempted at least one form of conservative (non-operative)
treatment (but this has not provided adequate relief of patient’s
pain/symptoms)
• Patient willing and able to give consent
Including but not limited to; medication, physiotherapy, modification of
daily activities
Exclusion criteria:
• Serious neurological deficit (e.g. foot-drop/possible cauda-equina
compression)
• Previous spinal surgery at the same intervertebral disc (level)
• Sciatica presentation for longer than 12 months
• Age < 16 years
• Age > 65 years
• Patient has not attempted any form of conservative treatment
• Any patient who has a contraindication for surgery and/or injection
• Patient known to be pregnant
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Outcomes
Primary outcome
The primary outcome is the Oswestry Disability
Questionnaire (ODQ) at 18 weeks after randomisation
(approximately 12 weeks after intervention).
Secondary outcomes
The secondary outcomes include the following:
1. ODQ score at 30, 42 and 54 weeks after
randomisation
2. Numerical rating scores for leg and back pain at
baseline, and at 18, 30, 42 and 54 weeks after
randomisation
3. To assess patient treatment satisfaction at 54 weeks
after randomisation
4. Modified Roland-Morris outcome score for sciatica
at baseline, and at 18, 30, 42 and 54 weeks after
randomisation
5. Core Outcomes Measures Index (COMI) at
baseline, and at 18, 30, 42 and 54 weeks after
randomisation
6. Work status (return to work and work days lost if
applicable) at 18 and 54 weeks after randomisation7. Cost-effectiveness, expressed as the incremental
cost per quality-adjusted life-year (QALY) based on
the EuroQol five-dimension, five-level quality of life
questionnaire (EQ-5D-5 L) at baseline, and at 18,
30, 42 and 54 weeks after randomisation
Monitoring, safety and quality control
Data will be collected using paper Case Report Forms
(CRFs) and patient-completed questionnaires during the
54-week follow-up period. Data capture will be monitored
in accordance with the Clinical Trials Research Centre’s
standard operating procedures to ensure compliance with
the International Conference on Harmonisation, Good
Clinical Practice and the Research Governance Framework
2005. Adverse events (AEs) are defined by the Medicines
for Human Use (Clinical Trials) Regulations 2004
(SI 2004/1031). AE data will be collected throughout
follow-up; the AE reporting period begins as soon as the
study intervention is received and ends 30 days after the
treatment visit. Serious adverse events (SAEs) and sus-
pected unexpected serious adverse reactions (SUSARs)
will be reported as per regulatory requirements. Safety
and other relevant data will be reviewed throughout the
trial by an Independent Data and Safety Monitoring
Committee and further oversight is provided by a Trial
Steering Committee.
Statistics
Statistical analysis
The ODQ is recommended as part of core outcome mea-
sures for low back research [15–18]. The scale ranges
from 100 (extreme disability) to 0 (extreme ability) [16]. A
change of 10 points has been widely accepted in the aca-
demic literature as the minimum clinical significance [17].
In order to detect a difference between two groups of 10
points on the ODQ at 5% significance level with 90%
power, a total of 172 participants are required. This as-
sumes a standard deviation (SD) of 20 points based on a
similar population in previously published trials [13–18].
Baseline ODQ data collected on 11 potentially eligible pa-
tients from the ‘fast-track sciatica clinic’ at The Walton
Centre generated an SD of 14.4, under the assumed value.
We therefore initially aimed to recruit a target of 200 pa-
tients to allow for a 10% rate of missing outcome data.
Randomisation was stratified by site. The primary outcome
(ODQ score at 18 weeks post randomisation) will be com-
pared between groups using a linear regression model, ad-
justed for the stratification variable centre, baseline ODQ
score, and possibly other (specified in advance) variables
considered to be potential confounders. Analysis of second-
ary outcomes will use similar methods, or logistic regression
analyses, where appropriate. The intention-to-treat principle
will be applied as far as is practically possible. The analysis
set for the primary outcome will include all participants
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mary outcome data will be assessed, blind to treatment
allocation, as to whether they are informative of likely
outcome. Participants with non-informative reasons for
missingness will be excluded from the primary analysis
set. Sensitivity analyses will be carried out using multiple
imputation to assess the robustness of the analysis to
missing primary outcome data.
Revision of sample size calculation
Due to recruitment difficulties early in the trial, the sam-
ple size calculation was revisited. The original calculation
did not assume any correlation between baseline and
follow-up ODQ scores, as no data was available to esti-
mate this. Based on a blinded analysis of the correlation
between baseline and follow-up ODQ scores in the first
47 trial participants to have outcome data available, this
correlation was estimated to be 0.49. Using this estimate,
the revised sample size to achieve 90% power was found
to be 66 per group. Allowing for 10% loss to follow-up
gives a revised target of 74 per group (148 total). The trial
was extended by the funder for a further 12 months and
Steering Committees decided to continue recruitment
until the end of the extension provided recruitment did
not exceed 200 subjects. The trial has now stopped re-
cruitment and 163 subjects were recruited.
Health economic analysis
The health economic analysis will adopt the perspective
of the NHS and Personal Social Services (PSS) and
additionally consider indirect costs such as time off work
(secondary analysis).
Resource use associated with secondary care will be ob-
tained from patient-level Hospital Episode Statistics (HES)
data obtained from NHS Digital. Patients’ use of primary
care services, personal social services, non-scheduled
clinic attendance, out-of-pocket expenditures and indirect
costs will be collected at baseline, treatment visit and at
18, 30, 42, 54 weeks post randomisation using a resource
use questionnaire. Unit cost data will be obtained from
standard sources (NHS reference costs and PSSRU Costs
of Health and Social Care).
The health outcome measure will be the QALY,
estimated by administering the EQ-5D-5 L at each
follow-up point. The number of QALYs experienced by
each patient will be calculated as the area under the
curve, using the trapezoidal rule, applying the UK tariffs
and corrected for baseline utility score.
Total costs will be combined with QALYs to calculate
the incremental cost-utility ratio which will be compared
with the £20,000 to £30,000 per QALY threshold of
cost-effectiveness specified by the National Institute for
Health and Care Excellence. Where appropriate, missing
resource use or health outcome data will be imputed. Arange of one-way sensitivity analyses will be conducted
to assess the robustness of the analysis, and multivariate
sensitivity analyses will be applied where interaction ef-
fects are suspected. The joint uncertainty in costs and
benefits will be considered through the application of
bootstrapping (10,000 replicates) and the estimation of
cost-effectiveness acceptability curves. We will also em-
ploy simple parametric approaches for analysing cost and
QALY data that assume normal distributions. Should the
data indicate otherwise, we will develop a generalised lin-
ear model to deal with problems such as skewness.
Dissemination of results
Study findings will be presented in conference abstracts,
poster presentations and scientific publications in
medical journals. The chief investigator will work with
the Trial Management Group and other principal inves-
tigators to generate manuscripts for publications.
Discussion
Surgical microdiscectomy for removal of PIDs has been
shown to successfully relieve symptoms in the majority of
patients [6, 11]. Disadvantages of surgery are the resource
implications for the NHS due to the requirement for hos-
pitalisation and the high skill level required of the treating
physician. Surgery also carries the highest level of risk of
all treatments for sciatica. Injections are relatively cheap
and low risk in comparison to sciatica; they are delivered
as a day-case procedure and the range of treatment pro-
viders is large, ranging from radiologists to surgeons or
pain physicians. There is potential that treatment adminis-
tered in the form of an injection may circumvent the need
for surgery. However, the true success rate of spinal injec-
tions is largely unknown and there is no evidence compar-
ing TFESI to surgical microdiscectomy that could be used
to advise one treatment pathway over another. This proto-
col describes the design of a RCT to evaluate the clinical
effectiveness and cost-effectiveness of TFESI to surgical
microdiscectomy to treat sciatica secondary to a PID. It is
the first randomised trial to address this issue to date.
Trial status
At the time of submission, the NERVES trial was closed to
recruitment. Twelve participating sites had recruited 163
patients (first patient randomised on 6 March 2015). An
internal pilot had been completed at two trial sites (The
Walton Centre, Liverpool, and Salford Royal Hospital) as
part of an initial feasibility study and followed the same
study procedures as for the main trial. The decision to pro-
gress to full trial was based on the pre-defined internal pilot
criteria for progression to a full trial. No between-group
statistical comparisons were carried out after the internal
pilot. Only the four criteria specified for progression to the
full trial were to be considered after the internal pilot.
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